Fresenius Kabi partners with Waltz Health to broaden direct access to biosimilars via Waltz Connect
Fresenius Kabi agreed to sell three biosimilars directly to employers, payers and pharmacy benefit managers through Waltz Health’s Waltz Connect platform. The arrangement uses transparent per-unit contract pricing and an EVERSANA-operated specialty pharmacy for home delivery.
1. Direct biosimilar access
Fresenius Kabi struck a deal with Waltz Health to sell three biosimilars directly to employers, payers and pharmacy benefit managers through the Waltz Connect platform. The model uses transparent per-unit contract pricing that avoids traditional rebates, while an EVERSANA-operated specialty pharmacy will dispense prescriptions and ship them to patients’ homes, bypassing wholesalers and rebate-driven pharmacy benefit manager channels.
